At Reuters Pharma USA in Philadelphia, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US ...

Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The partnership is set to progress the ...

Post-hoc analyses of the EFFISAYIL 2 trial revealed improvements in Psoriasis Symptom Scale (PSS), Pain Visual Analog Scale ...

The grand list of taxable property in Ridgefield totaled about $5.9 billion for 2024, an increase of about $42 million or ...

Advancement of AbbVie Inc. and OSE Immunotherapeutics strategic partnership to develop ABBV-230: in April 2024, the Hart-Scott-Rodino waiting period expired enabling teams to commence work around the ...

ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716 ...

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- ...

STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Boehringer Ingelheim, a leading biopharmaceutical company, has teamed up with the Emirates Thoracic Society (ETS) and social media influencer Ghaith Marwan to raise awareness of Interstitial Lung ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...